Project
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
Ongoing - recruitment active ยท 2023 until 2028
Fischer Stefanie, Harder Anja, Quinter Janine
No results found.